LoadingLoadingLoadingNet selling: insiders sold $873K and bought $493K on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (3)
Two Sigma
$81.6M
bought
Millennium
$71.1M
bought
Bank of America
$69.5M
bought
No tracked top-trader positions in ASND as of Oct 24, 07:41 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Aug 6, 2026
Period ending
Jun 30, 2026
Earnings per share
$0.78 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 23, 2026
EPS expected
$0.64 to $1.09
Revenue expected
17 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 6, 2026 | $3.29 / $0.78Alpha Vantage | +$2.51 beat | EUR 344.9M No estimate | Unavailable |
| Mar 31, 2026 | May 7, 2026 | $0.27 / $0.43Alpha Vantage | -37.21% miss | EUR 250.7M No estimate | Unavailable |
| Dec 31, 2025 | Feb 11, 2026 | -$0.55 / -$0.24Alpha Vantage | -129.17% miss | EUR 245.2M No estimate | Unavailable |
| Sep 30, 2025 | Nov 12, 2025 | -$1.00 / -$0.12Alpha Vantage | -$0.88 miss | EUR 213.6M No estimate | Unavailable |
| Jun 30, 2025 | Aug 7, 2025 | -$0.93 / -$1.42Alpha Vantage | +34.51% beat | EUR 158.0M No estimate | Unavailable |
| Mar 31, 2025 | May 1, 2025 | -$1.58 / -$1.51Alpha Vantage | -4.64% miss | $101.0M No estimate | Unavailable |
| Dec 31, 2024 | Feb 12, 2025 | -$0.64 / -$1.17Alpha Vantage | +45.30% beat | EUR 173.9M No estimate | Unavailable |
| Sep 30, 2024 | Nov 14, 2024 | -$1.72 / -$1.46Alpha Vantage | -17.81% miss | $57.8M No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Jun 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|
| What came in | |||
| Revenue | $36.0M | $57.8M | $101.0M |
| Cost of what it sold | $11.5M | $11.2M | $17.5M |
| Gross profit | $24.5M | $46.6M | $83.4M |
| What it spent | |||
| Research and development | $83.5M | $73.5M | $86.6M |
| Sales and admin | $72.3M | $68.1M | $95.6M |
| Other operating costs | $2.0M | $1.7M | $5.4M |
| Total operating expenses | $157.8M | $143.4M | $187.6M |
| What was left | |||
| Operating profit | -$133.3M | -$96.7M | -$104.2M |
| Interest on debt | $19.6M | $25.3M | $44.8M |
| Profit before tax | -$109.2M | -$98.2M | -$93.6M |
| Tax | $229.0K | $1.0M | $1.1M |
| Net profit | -$109.4M | -$99.2M | -$94.6M |
| EBITDA | -$85.1M | -$68.5M | -$44.2M |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
Ascendis Pharma A/S Estimates – NASDAQ:ASND
NeutralOct 23H.C. Wainwright Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $344
BullishOct 19ASND: Ascendis Pharma Latest Stock Price, Analysis, News and Trading Ideas
Leans bullishOct 19EU's CHMP gives positive opinion on weekly TransCon CNP for treating children's achondroplasia
BullishOct 17EMA panel backs Ascendis’ achondroplasia drug TransCon CNP
BullishOct 17EU advisers weigh in on once-weekly TransCon CNP for children at Ascendis Pharma (ASND)
BullishOct 16UBS Adjusts Ascendis Pharma A/S Price Target to $269 From $307, Maintains Buy Rating
Leans bearishOct 16Ascendis Pharma Receives Positive CHMP Opinion for EU Marketing Authorization of Once-Weekly TransCon CNP for Achondroplasia
BullishOct 16
